Loading...
XNAS
CERS
Market cap631mUSD
Jul 09, Last price  
3.15USD
1D
0.32%
1Q
66.67%
Jan 2017
-27.59%
Name

Cerus Corp

Chart & Performance

D1W1MN
XNAS:CERS chart
P/E
—
P/S
3.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.06%
Rev. gr., 5y
17.53%
Revenues
206m
+14.35%
35,580,00011,044,00016,507,00017,982,00023,109,00033,044,00036,695,00039,657,00036,503,00034,223,00037,183,00043,568,00060,908,00074,649,00091,920,000130,859,000162,048,000156,367,000180,270,000206,133,000
Net income
-16m
L-25.29%
-4,779,000-45,304,000-29,181,000-24,135,000-16,911,000-16,982,000-15,917,000-43,337,000-38,566,000-55,868,000-62,906,000-60,585,000-57,564,000-71,244,000-59,857,000-54,374,000-42,779,000-37,489,000-20,918,000-15,627,000
CFO
11m
0.00%
-14,685,000-37,402,000-34,545,000-14,664,000-14,111,000-15,632,000-13,917,000-26,797,000-39,811,000-51,129,000-53,529,000-52,235,000-31,246,000-65,499,000-41,811,000-33,922,000-25,615,000-43,168,00011,359,00011,359,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
URL
https://www.cerus.com/
IPO date
Jan 31, 1997
Employees
665
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT